JP2016532667A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532667A5
JP2016532667A5 JP2016521758A JP2016521758A JP2016532667A5 JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5 JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016521758 A JP2016521758 A JP 2016521758A JP 2016532667 A5 JP2016532667 A5 JP 2016532667A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical combination
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532667A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059387 external-priority patent/WO2015054175A1/en
Publication of JP2016532667A publication Critical patent/JP2016532667A/ja
Publication of JP2016532667A5 publication Critical patent/JP2016532667A5/ja
Priority to JP2018225287A priority Critical patent/JP7403950B2/ja
Pending legal-status Critical Current

Links

JP2016521758A 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ Pending JP2016532667A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018225287A JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361889640P 2013-10-11 2013-10-11
US61/889,640 2013-10-11
US201361911089P 2013-12-03 2013-12-03
US61/911,089 2013-12-03
PCT/US2014/059387 WO2015054175A1 (en) 2013-10-11 2014-10-07 Combinations of histone deactylase inhibitors and immunomodulatory drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018225287A Division JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Publications (2)

Publication Number Publication Date
JP2016532667A JP2016532667A (ja) 2016-10-20
JP2016532667A5 true JP2016532667A5 (https=) 2017-11-16

Family

ID=52810182

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016521758A Pending JP2016532667A (ja) 2013-10-11 2014-10-07 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018225287A Active JP7403950B2 (ja) 2013-10-11 2018-11-30 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2021020680A Pending JP2021073314A (ja) 2013-10-11 2021-02-12 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JP2023184173A Pending JP2024010118A (ja) 2013-10-11 2023-10-26 ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ

Country Status (17)

Country Link
US (3) US20150105358A1 (https=)
EP (1) EP3054939A4 (https=)
JP (4) JP2016532667A (https=)
KR (1) KR20160060143A (https=)
CN (1) CN105722507A (https=)
AU (1) AU2014332147A1 (https=)
CA (1) CA2926808A1 (https=)
CL (1) CL2016000838A1 (https=)
CR (1) CR20160200A (https=)
EA (1) EA201690753A1 (https=)
IL (1) IL244923A0 (https=)
MX (1) MX2016004604A (https=)
NI (1) NI201600051A (https=)
PE (1) PE20161342A1 (https=)
PH (1) PH12016500649A1 (https=)
SG (1) SG11201602791RA (https=)
WO (1) WO2015054175A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI600638B (zh) 2010-01-22 2017-10-01 艾斯特隆製藥公司 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
BR112013011868A2 (pt) 2010-11-16 2016-08-23 Acetylon Pharmaceuticals Inc compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
ES2929576T3 (es) * 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
WO2015054474A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
CA2926808A1 (en) * 2013-10-11 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
CR20160308A (es) 2013-12-03 2016-11-08 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
AU2015360270B9 (en) 2014-12-12 2019-12-05 Regenacy Pharmaceuticals, Llc Piperidine derivatives as HDAC1/2 inhibitors
AR105812A1 (es) 2015-06-08 2017-11-15 Acetylon Pharmaceuticals Inc Métodos para la preparación de inhibidores de proteína deacetilasa
AR104935A1 (es) 2015-06-08 2017-08-23 Acetylon Pharmaceuticals Inc Formas cristalinas de un inhibidor de histona deacetilasa
US11311540B2 (en) * 2016-02-17 2022-04-26 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
TW201803594A (zh) 2016-06-09 2018-02-01 達納-法伯癌症協會 Hdac抑制劑與bet抑制劑之使用方法及醫藥組合
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
JP7516047B2 (ja) * 2016-11-23 2024-07-16 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とcd38阻害剤とを含む医薬組み合わせ物及びその使用方法
US11497746B2 (en) * 2016-11-23 2022-11-15 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ(hdac)阻害剤
TWI600638B (zh) * 2010-01-22 2017-10-01 艾斯特隆製藥公司 作爲蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
BR112013011868A2 (pt) * 2010-11-16 2016-08-23 Acetylon Pharmaceuticals Inc compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
US9512083B2 (en) * 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
CA2926808A1 (en) * 2013-10-11 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs

Similar Documents

Publication Publication Date Title
JP2016532667A5 (https=)
JP2017524735A5 (https=)
JP2016536286A5 (https=)
JP2016515561A5 (https=)
JP2017518334A5 (https=)
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
JP2014507446A5 (https=)
MY170656A (en) Kinase inhibitors
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
JP2015078230A5 (https=)
EA201790088A1 (ru) Ингибиторы syk
JP2014508804A5 (https=)
JP2016518337A5 (https=)
JP2016514159A5 (https=)
JP2012144574A5 (https=)
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
JP2013509429A5 (https=)
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
WO2015187542A8 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
JP2011088926A5 (https=)
PH12014501278A1 (en) Kinase inhibitors
MX376029B (es) Compuestos de isoindol.